Navigation Links
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
Date:6/8/2009

Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, 200 milligrams (mg) Dosing over Five to Seven Days of Treatment

SAN DIEGO, June 8 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 2 clinical trial evaluating the safety and efficacy of oral torezolid (TR-701), its investigational antibiotic for the treatment of severe complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria, especially drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). The study achieved its primary goals of establishing safety and efficacy in all doses evaluated.

In the randomized, double-blind, dose-ranging study conducted at eight centers in the U.S., torezolid was administered orally at doses of 200, 300 or 400 mg once-daily for five to seven days of treatment. Of the 188 patients who received drug, 164 (87%) were clinically evaluable at the test-of-cure visit. The overall cure rates of clinically evaluable patients for severe abscesses, cellulitis and wound infections were 96%, 97% and 90%, respectively. Clinical outcomes were not affected by the size of lesions. Clinical cure rates by dose in the clinically evaluable population were 98%, 94% and 94% for the 200, 300 and 400 mg doses, respectively. In the group of microbiologically evaluable patients (133, 71%), clinical cure was achieved in 100%, 93% and 96% of patients receiving 200, 300 or 400 mg doses, respectively. There were no clinical relapses at the late follow-up visit 21-28 days post treatment. Highlighting the growing problem of drug resistance in the community, MRSA was the primary pathogen in 72% of the microbiologically evaluable patients.

"I was impressed by the rapid clinical effect of oral torezolid in curing severe skin infections caused by MRSA and other gram-positive pathogens," said Dr. Joseph Surber, Chief Medical Officer, Southeas
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
2. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
3. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
4. Trius Doses First Patient in Antibacterial Phase 2 Trial
5. PacificGMP Completes GMP Product Fill for Trius Therapeutics
6. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
7. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Krakauer , Chief Executive Officer, will be presenting at the ... New York Palace Hotel in New York ... 2014 at 2:00 PM ET. In addition, Mr. Krakauer and ... available for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... , Nov. 20, 2014  The acceptance of ... 2014 AAGL Global Congress demonstrates continued interest in ... to provide bowel control. One of the abstracts, presented ... and Division Chief of Urogynecology and Reconstructive Pelvic ... an Award for Best Written Abstract on Urogynecology/Pelvic ...
(Date:11/21/2014)... , Nov. 20, 2014   Coqui RadioPharmaceuticals ... the first U.S. commercial producer of Molybdenum-99 (Mo-99), is ... with INVAP to design its Medical Isotope ... Mo-99 is the parent isotope of Technetium-99, which ... worldwide. In 2012, Congress passed legislation making it a ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... CITY, June 23, 2011 PD-Rx Pharmaceuticals, Inc., ... the purchase of the Washington EMR, an electronic ... Washington EMR is the premier quality, low-cost ... The intuitive interface allows the physician and assistants ...
... SAN DIEGO, June 23, 2011 BioSurplus today announced ... of instruments worth over $10 million will be auctioned ... The first auction will have choice laboratory equipment ... HPLCs and Mass Specs, Molecular Devices Spectramax M5 plate ...
Cached Medicine Technology:PD-Rx Pharmaceuticals Acquires Wilson Medical's EMR 2BioSurplus Selected to Auction $10 Million in Lab Equipment 2
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has unveiled its new ... are now offered at deeply discounted prices, up to 75 ... Dec. 15. The main purpose of the promotion is to ... items are ideal options for ladies who are eager to ... its new mint cocktail dresses are very beautiful; they are ...
(Date:11/23/2014)... 2014 Nearly 260 testosterone lawsuits ... deep vein thrombosis and other serious cardiovascular events ... litigation (MDL) underway in the Northern District of ... documents updated on November 17th by the U.S. ... filing of 259 lawsuits against the makers of ...
(Date:11/23/2014)... To show thanks to new and old customers, iFitDress.com ... dresses for weddings. Customers who need custom outfits can ... distinguished dress manufacturer, and it is among the ones which ... very long time. The CEO of this company says, "iFitDress.com ... to buy not only a beautiful dress, but also a ...
(Date:11/23/2014)... 2014 “BlackVue” was featured on NewsWatch ... which features the latest and coolest technology products available ... for NewsWatch, conducted the product review and shared with ... options in the car camera industry. , The need ... be hard to find the one that’s right per ...
(Date:11/23/2014)... Utah (PRWEB) November 23, 2014 ... insurance reimbursement for small businesses, announced their new ... The End of Employer-Provided Health Insurance. ... is the greatest financial risk facing most American ... U.S. employers, small and large, when it comes ...
Breaking Medicine News(10 mins):Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2
... have hit a plateau, report says , , TUESDAY, April ... death rates seem to have stagnated, a new report ... that fueled recent declines in cancer deaths appear to ... terms of people smoking and getting necessary screening. The ...
... Board of Directors, SAN JOSE, Calif., April ... home improvement retailer, today announced a,partnership with Canary ... the funding, discovery and development of,tests for early ... OSH has been appointed to Canary Foundation,s Board ...
... spike in blood flow to heart, study finds , , ... a gene variation in heart disease patients who are ... that it causes a major reduction in blood flow ... with this particular variation of the adrenergic beta-1 receptor ...
... are dying even sooner than before, report shows , , ... belief, life expectancies are not rising steadily and uniformly ... shows that between 1983 and 1999, death rates for ... geographical and racial disparities in life expectancy have worsened ...
... PORTLAND, Ore. An Oregon Health & Science University ... a strong indicator of survival for men with advanced ... is a special type of protein produced by the ... "This could mean that a simple blood test that ...
... The Robert Wood Johnson Foundations Physician Faculty Scholars ... Jane Brotanek, assistant professor of pediatrics at UT Southwestern ... which investigates the relationship between infant feeding practices and ... one of a small group of junior faculty nationwide ...
Cached Medicine News:Health News:Factors in Cancer Death Rates Stay Stagnant 2Health News:Factors in Cancer Death Rates Stay Stagnant 3Health News:Orchard Supply Hardware Partners With Canary Foundation 2Health News:Orchard Supply Hardware Partners With Canary Foundation 3Health News:Gene Variant Boosts Risk for Stress-Related Ischemia 2Health News:Disparities in Life Expectancy Increasing 2Health News:Disparities in Life Expectancy Increasing 3Health News:OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival 2Health News:UT Southwestern Medical Center receives grant from the Robert Wood Johnson Foundation 2
... provide molecular labs a more advanced alternative ... our MGB technology, combined with post-PCR dissociation ... to provide molecular labs more powerful tools ... organisms or genetic mutations associated with disease, ...
... are specifically designed for PCR amplification ... fluorescence detection systems. The NGEN product ... of mutations associated with cystic fibrosis, ... as reagents for the detection of ...
... Reagents provide molecular labs a more advanced ... using our MGB technology, combined with post-PCR ... able to provide molecular labs more powerful ... specific organisms or genetic mutations associated with ...
... In pregnancy testing, our new ICON 25 ... gives you fast, accurate results, plus Beckman ... 25 hCG offers CLIA waived simplicity for ... serum. For the hospital, it's the perfect ...
Medicine Products: